An emulsion in water containing abamectin and phosphorothiolate and its preparation method

Abstract

The application provides an aqueous emulsion containing abamectin and fostedil, which comprises, in percentage by mass, 10-50% of a pharmaceutical active ingredient, 2-10% of an emulsifier, 0.5-8% of a dispersing agent, 10-40% of a solvent, 1-6% of a cosolvent, 3-8% of an antifreezing agent, 0.1-2% of a stabilizer, and the rest of water; the pharmaceutical active ingredient comprises abamectin and fostedil. The mass ratio of the above-mentioned components is optimized, the product efficacy is improved, and the frequency of administration is reduced. The product stability is improved by optimizing the auxiliary agent, the influence of environmental changes during transportation is effectively solved, and the risks of stratification, demulsification, water separation and crystallization are avoided. The decomposition of the active ingredient is also solved, the application meets the use requirements of different countries and regions, and is conducive to wide popularization and application.

Description

[0001] This application is a divisional application filed on August 23, 2023, with application number 202311069801.9, entitled "An emulsion containing abamectin and thiazophosphonates and its preparation method". Technical Field

[0002] This invention relates to the field of pesticide formulation technology, and in particular to an emulsifiable concentrate containing abamectin and thiazophos and its preparation method. Background Technology

[0003] Abamectin has stomach poison and contact action against mites and insects, but it does not kill eggs. Its mechanism of action involves interfering with neurophysiological activity, stimulating the release of γ-aminobutyric acid (GABA), which inhibits nerve conduction in arthropods. It is primarily used to control resistant pests such as diamondback moth, leaf miner, and spider mites.

[0004] Fosthiazate is an organophosphate nematicide that works by inhibiting the synthesis of acetylcholinesterase in root-knot nematodes. It has strong contact toxicity and is also highly effective against some pests that have developed resistance to traditional insecticides. It is used to control nematodes, aphids, and other pests.

[0005] Avermectin Thiazolylphosphine compositions have been shown to have significant synergistic effects, reducing the dosage of the active ingredient, which not only lowers costs but, more importantly, reduces harm to plants. However, the quality of these products is currently unstable, and they are highly susceptible to environmental changes during sea transport, easily leading to phenomena such as stratification, demulsification, and water separation, posing a risk of crystallization. Furthermore, their low flash point makes the active ingredient easily degraded, severely impacting efficacy and hindering the use and promotion of these products. Summary of the Invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide an aqueous emulsion containing abamectin and thiazophosphonates and its preparation method, which has high stability.

[0007] This invention provides an aqueous emulsion containing abamectin and thiazophos, comprising, by weight percentage: The active pharmaceutical ingredient is 10%-50%, emulsifier is 2%-10%, dispersant is 0.5%-8%, solvent is 10%-40%, cosolvent is 1%-6%, antifreeze is 3%-8%, stabilizer is 0.1%-2%, and deionized water is added to make up 100%. The active pharmaceutical ingredients include avermectin and thiazophosphonates.

[0008] The preferred mass content of the active pharmaceutical ingredient is 10% to 30%.

[0009] The present invention uses avermectin and thiazophosphonate as active pharmaceutical ingredients. The mass ratio of avermectin to thiazophosphonate is preferably 1: (1~50), more preferably 1: (5~20). In some specific embodiments of the present invention, the mass ratio of avermectin to thiazophosphonate includes, but is not limited to, 1:5, 1:9, 1:10, 1:15, and 1:19.

[0010] Avermectin: Appearance: pale yellow to white crystalline powder, odorless. Melting point: 155–157℃, vapor pressure: 2 × 10⁻⁶. - 7 Pa, relative density 1.16 (21℃). Solubility at 21℃: toluene 350 g / L, acetone 100 g / L, isopropanol 70 g / L, chloroform 25 g / L, ethanol 20 g / L, methanol 19.5 g / L, cyclohexane 6 g / L, kerosene 0.5 g / L, water 10 μg / L. LogP value 4.4 ± 0.3. Stable under normal conditions, and does not hydrolyze at pH 5–9.

[0011] Thiazolphosphine: The pure product is a pale yellow liquid. Melting point <25℃, relative density 1.26 (20℃), boiling point 198℃, vapor pressure 5.6×10⁻⁶. -4 Pa (25℃) has a solubility of 9.85 g / L (0.87%) in water and a partition coefficient of 1.75.

[0012] From the perspective of their properties, avermectin has requirements regarding the type and amount of solvent used, and the combination of emulsifier and dispersant determines the spontaneous dispersibility and emulsion stability of the formulation in water. Avermectin also carries the risk of degradation. This invention involves extensive screening of the adjuvant system, ultimately yielding a system with optimal compatibility among the components. In particular, the screening and combination of emulsifier and dispersant improves the stability of the dosage form, providing advantages such as good emulsification and dispersibility, and resistance to transportation. This effectively solves problems such as sample precipitation, poor dispersion, emulsion instability, and easy decomposition.

[0013] The water-in-oil emulsion provided by the present invention contains an emulsifier, the mass content of which is preferably 2%-10%, more preferably 2%-8%. In some specific embodiments of the present invention, the mass content of the emulsifier is specifically 2%, 4%, 6% or 8%.

[0014] The present invention preferably employs a composite emulsifier, wherein the emulsifier comprises a first emulsifier and a second emulsifier.

[0015] Preferably, the first emulsifier is selected from one or more of octylphenol polyoxyethylene polyoxypropylene ether, cyclohexene polyoxyethylene polyoxypropylene, benzyl biphenol polyoxyethylene polyoxypropylene, benzylphenol polyoxyethylene polyoxypropylene, phenethylphenol polyoxyethylene ether polyoxypropylene ether, isopropylphenyl phenethylphenol polyoxyethylene ether, styrene phenol polyoxyethylene ether, octylphenol polyoxyethylene ether, sec-octylphenol polyoxyethylene ether, nonylphenol polyoxyethylene ether, dinonylphenol polyoxyethylene ether, benzylphenol polyoxyethylene ether, fatty lauryl alcohol polyoxyethylene ether, oleyl alcohol polyoxyethylene ether, isotridecyl alcohol polyoxyethylene ether, fatty acid polyoxyethylene ether, fatty amine polyoxyethylene ether, and methyl alcohol polyoxyethylene ether; more preferably, it is one or more of methyl alcohol polyoxyethylene ether and nonylphenol polyoxyethylene ether; and even more preferably, it is methyl alcohol polyoxyethylene ether.

[0016] Preferably, the second emulsifier is selected from one or more of glycerol esters, polyglycerol esters, glycol esters, EO-PO block polyethers, calcium dodecylbenzene sulfonate, stilbene-phenol polyoxymethylene condensate, triglyceride monostearate, arylphenol polyoxyethylene ether formaldehyde condensate, stearate, polyoxyethylene oleate, castor oil polyoxyethylene ether phosphate, sorbitan ester ether, polyglycerol fatty acid ester, succinate sulfonate, α-sulfofatty acid ester salt, and polyarylphenol ether sulfate; more preferably, it is selected from one or more of EO-PO block polyethers and calcium dodecylbenzene sulfonate; and even more preferably, it is selected from EO-PO block polyethers.

[0017] The emulsion contains a dispersant, and the mass content of the dispersant is preferably 0.5%-8%, more preferably 1%-2%. In some specific embodiments of the present invention, the mass content of the dispersant is 1%, 1.5% or 2%.

[0018] Preferably, the dispersant is selected from one or more of the following: high molecular weight polymer, sodium polystyrene acrylate, maleic rosin block polyether sulfonate ammonium salt, diisopropylnaphthalene sulfonate sodium salt, benzylnaphthalene sulfonate formaldehyde condensate sodium salt, styrene acrylate copolymer sodium salt, tristyrene-phenol polyoxyethylene ether phosphate triethanolamine salt, maleic rosin block polyether sulfonate ammonium salt, styrene-maleic anhydride copolymer sodium salt, maleic anhydride copolymer sodium salt, maleic anhydride acrylate copolymer, fatty alcohol polyoxyethylene polyoxypropylene ether, styrene-maleic anhydride copolymer sodium salt, alkanolamide polyoxyethylene ether phosphate, sodium lignosulfonate, calcium lignosulfonate, diethylsuccinate sodium sulfate, and acrylate malebutadiene styrene sulfonate sodium salt; more preferably, it is selected from one or more of tristyrene-phenol polyoxyethylene ether phosphate triethanolamine salt and benzylnaphthalene sulfonate formaldehyde condensate sodium salt; even more preferably, it is selected from tristyrene-phenol polyoxyethylene ether phosphate triethanolamine salt or benzylnaphthalene sulfonate formaldehyde condensate sodium salt.

[0019] The mass ratio of the first emulsifier, the second emulsifier, and the dispersant is preferably 1-4:1-4:1-4, more preferably 1-2:1-2:1-2, and even more preferably 1.5:1.5:1.

[0020] In some specific embodiments of the present invention, the first emulsifier, the second emulsifier, and the dispersant are, in sequence, methyl alcohol polyoxyethylene ether, EO-PO block polyether, and tristyrene-phenylphenol polyoxyethylene ether phosphate triethanolamine salt, with mass contents of 3%, 3%, and 2%, respectively.

[0021] In some specific embodiments of the present invention, the first emulsifier, the second emulsifier, and the dispersant are, in sequence, methyl alcohol polyoxyethylene ether, EO-PO block polyether, and sodium salt of benzyl naphthalene sulfonic acid formaldehyde condensate, with mass contents of 3%, 3%, and 2%, respectively.

[0022] In some specific embodiments of the present invention, the first emulsifier, the second emulsifier, and the dispersant are, in sequence, methyl alcohol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, with mass contents of 3%, 3%, and 1%, respectively.

[0023] In some specific embodiments of the present invention, the first emulsifier, the second emulsifier, and the dispersant are, in sequence, nonylphenol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, with mass contents of 3%, 3%, and 1%, respectively.

[0024] In some specific embodiments of the present invention, the first emulsifier, the second emulsifier, and the dispersant are nonylphenol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, respectively, with mass contents of 1%, 1%, and 1%, respectively.

[0025] In some specific embodiments of the present invention, the first emulsifier, the second emulsifier, and the dispersant are, in sequence, nonylphenol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, with mass contents of 1%, 1%, and 1.5%, respectively.

[0026] In some specific embodiments of the present invention, the first emulsifier, the second emulsifier, and the dispersant are nonylphenol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, respectively, with mass contents of 4%, 4%, and 1%.

[0027] Experimental studies have demonstrated that by screening the first emulsifier, the second emulsifier, and the dispersant, the effects of avermectin can be significantly influenced. The stability of thiazophosphonate water-in-water emulsions includes spontaneous dispersibility in water, high and low temperature storage stability, and crystallization. This invention involves extensive screening of the adjuvant system, ultimately yielding a system with optimal compatibility among the aforementioned components, particularly the combination of emulsifier and dispersant. This solves the problem of significant avermectin decomposition in the product, greatly improving product stability and offering the advantage of excellent emulsification and dispersibility. It effectively mitigates the impact of environmental changes during transportation, avoiding the risks of stratification, demulsification, water separation, and crystallization, and also addresses the issue of active ingredient decomposition.

[0028] The specific combination of the first emulsifier, the second emulsifier, and the dispersant described above can achieve the best results.

[0029] The water-based emulsion contains a solvent, and the mass content of the solvent is preferably 10%-40%, more preferably 15%-40%. In some specific embodiments of the present invention, the mass content of the solvent is 15%, 32%, or 40%.

[0030] Preferably, the solvent is selected from one or more of solvent oil S-200, solvent oil S-150, solvent oil S-100, N,N-dimethyldecylamide, and cyclohexanone; more preferably, it is selected from one or more of solvent oil S-200 and solvent oil S-150.

[0031] The water-based emulsion contains a co-solvent, and the mass content of the co-solvent is preferably 1%-6%, more preferably 2%-4%. In some specific embodiments of the present invention, the mass content of the co-solvent is 2%, 3% or 4%.

[0032] Preferably, the co-solvent is selected from one or more of N-methylpyrrolidone, isophorone, dimethyl sulfoxide, and methyl oleate; more preferably, it is selected from one or more of N-methylpyrrolidone and isophorone.

[0033] The emulsion contains an antifreeze agent, and the mass content of the antifreeze agent is preferably 3%-8%, more preferably 5%-8%. In some specific embodiments of the present invention, the mass content of the antifreeze agent is 5%, 6%, 7% or 8%.

[0034] Preferably, the antifreeze is selected from one or more of urea, potassium chloride, ethylene glycol, propylene glycol, polyethylene glycol, and sodium chloride; more preferably, it is selected from one or more of ethylene glycol and polyethylene glycol.

[0035] The aqueous solvent contains a stabilizer, and the mass content of the stabilizer is preferably 0.1%-2%, more preferably 1%-2%. In some specific embodiments of the present invention, the mass content of the stabilizer is 1% or 2%.

[0036] Preferably, the stabilizer is selected from one or more of butylated hydroxyl, butylated hydroxyanisole, propyl gallate, sodium carbonate, and o-hydroxydimethyl ketone; more preferably, it is selected from one or more of butylated hydroxytoluene and butylated hydroxyanisole.

[0037] In some specific embodiments of the present invention, the solvent, cosolvent, antifreeze and stabilizer are solvent oil S-200, N-methylpyrrolidone, ethylene glycol and dibutylhydroxytoluene, respectively, with mass contents of 32%, 2%, 5% and 1% respectively.

[0038] In some specific embodiments of the present invention, the solvent, cosolvent, antifreeze and stabilizer are solvent oil S-150, isophorone, ethylene glycol and dibutylhydroxytoluene, respectively, with mass contents of 32%, 2%, 5% and 1% respectively.

[0039] In some specific embodiments of the present invention, the solvent, cosolvent, antifreeze and stabilizer are solvent oil S-150, isophorone, ethylene glycol and butylated hydroxyanisole, respectively, with mass contents of 40%, 2%, 5% and 1% respectively.

[0040] In some specific embodiments of the present invention, the solvent, cosolvent, antifreeze and stabilizer are solvent oil S-150, isophorone, polyethylene glycol and butylated hydroxyanisole, respectively, with mass contents of 15%, 2%, 8% and 2% respectively.

[0041] The water-based emulsion provided by this invention also contains a surplus of water.

[0042] This invention provides a method for preparing the above-mentioned aqueous emulsion containing abamectin and thiazophos, comprising the following steps: S1) Mix the antifreeze and water evenly to obtain an aqueous phase; The active pharmaceutical ingredient, emulsifier, dispersant, solvent, cosolvent, and stabilizer are mixed to obtain an oil phase; S2) The above aqueous phase and oil phase are mixed to obtain an emulsion containing abamectin and thiazophos.

[0043] Preferably, in the above mixing process, each material is subjected to high-speed shearing at a shearing rate of 1000-10000 r / min.

[0044] This invention does not impose any particular limitation on the feeding method of the above-mentioned materials, and any feeding method disclosed in the prior art can be used. Preferably, after homogenization, the particle size distribution is detected by a laser particle size analyzer until the particle size D90 is less than 1.2µm.

[0045] Compared with existing technologies, this invention provides a water-in-oil emulsion containing abamectin and thiazophosphonate, comprising, by mass percentage: 10%-50% active pharmaceutical ingredient, 2%-10% emulsifier, 0.5%-8% dispersant, 10%-40% solvent, 1%-6% cosolvent, 3%-8% antifreeze, 0.1%-2% stabilizer, and deionized water to make up to 100%; the active pharmaceutical ingredient includes abamectin and thiazophosphonate. This invention optimizes the above mass ratio, improving the efficacy of the product while reducing the amount of insecticide used and the frequency of application, thereby lowering the cost of the pesticide. By selecting superior adjuvants, this invention improves product stability, effectively addressing the impact of environmental changes during transportation and avoiding the risks of stratification, demulsification, water separation, and crystallization. It also solves the problem of active ingredient decomposition, meeting the needs of different countries and regions, and facilitating widespread application. Detailed Implementation

[0046] To further illustrate the present invention, the following detailed description of the aqueous emulsion containing abamectin and thiazophos and its preparation method, with reference to embodiments, is provided by the present invention.

[0047] Examples 1-8

[0048] According to the proportions in Table 1, add the antifreeze and water into the reactor and mix thoroughly to disperse evenly; add the active ingredient, emulsifier, dispersant, solvent, cosolvent, and stabilizer into the oil phase reactor. After complete dissolution, mix the oil phase with the water phase to obtain an emulsion containing abamectin and thiazophos.

[0049] Comparative Examples 1-2

[0050] The preparation method is the same as in Examples 1-8, and the proportions of each group are shown in Table 1.

[0051] Table 1. Raw material ratios (mass percentage) for Examples 1-8 and Comparative Examples 1-2

[0052]

[0053]

[0054] The performance of the water-in-oil emulsions prepared in Examples 1-8 and Comparative Examples 1-2 was tested, and the results are shown in Table 2 below.

[0055] Table 2. Avermectin prepared in Examples 1-8 and Comparative Examples 1-2 Thiazolphosphine water-based emulsion product performance

[0056]

[0057]

[0058] Example 9: Single-factor controlled experiment

[0059] Based on Example 1, the first emulsifier, methyl alcohol polyoxyethylene ether, was replaced with polyurethane, while the contents of all other materials remained unchanged, to prepare an emulsion, denoted as 1#.

[0060] Based on Example 1, the second emulsifier EO-PO block polyether was replaced with agricultural emulsion 700#, while the contents of all other materials remained unchanged, and an emulsion was prepared, which was designated as 2#.

[0061] Based on Example 1, the dispersant tristyrylphenol polyoxyethylene ether phosphate triethanolamine salt was replaced with alkylbenzene sulfonate, while the contents of all other materials remained unchanged, and an emulsion was prepared, denoted as 3#.

[0062] Based on Example 1, solvent oil S-200 was replaced with toluene, while all other materials and their contents remained unchanged, to prepare an emulsion, denoted as 4#.

[0063] Based on Example 1, the stabilizer dibutylhydroxytoluene was replaced with triisopropanolamine, while the contents of all other materials remained unchanged, and an emulsion was prepared, denoted as 5#.

[0064] The properties of the prepared water-in-oil emulsion were tested, and the results are shown in Table 3 below.

[0065] Table 3 Avermectin Performance of thiazophosphine emulsions 1#-5#

[0066]

[0067] Test Example 3: Indoor toxicity test of thiazophosphonates and avermectin: Pepper root-knot nematode masses were collected from pepper fields in Hualong Town, Shouguang City, Shandong Province. Indoor toxicity tests were conducted in the laboratory of Weifang Runfeng Chemical Co., Ltd., using second-instar larvae for the experiments. Egg masses of the root-knot nematode were isolated from the roots of diseased plants. After purification and culture, single egg masses were inoculated onto pepper roots. Diseased roots were collected, cut into approximately 2 cm segments, and rinsed in a 1% sodium hypochlorite solution for about 4 minutes. Nematode eggs were then collected by rinsing with 200-mesh and 500-mesh nematode sieves. The eggs were diluted with distilled water to a concentration of 200 nematodes / mL. The egg solution was dropped onto a shallow dish lined with two layers of paper towels and left for 3 days. The hatched second-instar larvae were then collected and a suspension was prepared for bioassay. Experimental method: Using a pipette, 2 mL of the drug solution was sequentially added to test tubes from low to high concentration. Then, 2 mL of the prepared nematode suspension was added to the culture tube, ensuring equal volume of the drug solution and nematode suspension (100 nematodes / mL). The treated samples were incubated in a (25±1)℃ incubator. 24 h after treatment, 1 mL of the sample was aspirated and microscopically examined using a counting dish to determine the mortality of the nematodes. Each sample was tested three times. The results are shown in Table 4.

[0068] This invention employs an indoor toxicity determination method. Indoor toxicity determination is performed according to the Sun Yunpei method to determine the co-toxicity coefficient (CTC) of two agents mixed in a certain proportion. CTC < 80 indicates antagonistic effect, 80 ≤ CTC ≤ 120 indicates additive effect, and CTC > 120 indicates synergistic effect.

[0069] All test reagents were provided by Shandong Weifang Runfeng Chemical Co., Ltd.

[0070] Table 4 Indoor toxicity data

[0071]

[0072] Indoor toxicity tests showed that the combination of thiazophos and abamectin had a significant synergistic effect, and the effect on pepper root-knot nematodes was significantly better than that of the single agent. Moreover, the synergistic effect was better when the mass ratio of abamectin to thiazophos was 1:19.

[0073] Experiment Example 4: Field efficacy trials of thiazophos and avermectin: This experiment was conducted in a chili greenhouse at a vegetable base in Shouguang City. The control agents were 20% thiazophos hydrochloride emulsion (commercially available) and 1.8% abamectin emulsion (commercially available). Five treatments were set up: Treatment 1: water spray, blank control; Treatment 2: Example 1; Treatment 3: Example 5; Treatment 4: 20% thiazophos hydrochloride emulsion; Treatment 5: 1.8% abamectin emulsion. Each plot was 20m². 2 The neighborhoods are arranged randomly.

[0074] Table 5. Dosage of each experimental group

[0075]

[0076] Prepare a solution by diluting the formulation with 400L of water per acre and then applying it to the roots of the plants. Calculate the total amount of solution needed for each plot and apply it evenly to the roots. The weather was good during application, and no adverse weather conditions occurred on the day of application.

[0077] Field efficacy trial investigation, calculation, and statistical methods for root-knot nematodes: Specifically, five random sampling points were taken from each plot, with soil samples collected from the crop root circumference (0–20 cm depth) at each point, for a total sampling volume of 500 mL. After soil collection, the samples were brought back to the laboratory for isolation using the shallow dish method, and the number of isolated nematodes was recorded. Examinations were conducted at 30 days and 60 days after application. The results are shown in Table 6.

[0078] Insect population reduction rate (%) =

[0079] Prevention and control effect (%) =

[0080] Table 6. Field efficacy test results of various treatments for controlling root-knot nematodes in peppers.

[0081]

[0082] Field efficacy trials showed that the combination of thiazophos and abamectin had a significant synergistic effect. Under normal use, the control efficacy against pepper root-knot nematodes was significantly better than that of a single agent. Furthermore, Example 1 achieved more stable physical indicators and lower formulation dosage through the optimization of adjuvants.

[0083] The above description of the embodiments is only for the purpose of helping to understand the method and core ideas of the present invention. It should be noted that those skilled in the art can make several improvements and modifications to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the protection scope of the claims of the present invention.

Claims

1. A water-in-oil emulsion containing abamectin and thiazophos, characterized in that, In terms of mass percentage, including: The active pharmaceutical ingredient is 10%-50%, emulsifier is 2%-10%, dispersant is 0.5%-8%, solvent is 10%-40%, cosolvent is 1%-6%, antifreeze is 3%-8%, stabilizer is 0.1%-2%, and deionized water is added to make up 100%. The active pharmaceutical ingredients include avermectin and thiazophos; The emulsifier includes a first emulsifier and a second emulsifier; The first emulsifier is selected from one or more of the following: octylphenol polyoxyethylene polyoxypropylene ether, cyclohexene polyoxyethylene polyoxypropylene, benzyl biphenol polyoxyethylene polyoxypropylene, benzylphenol polyoxyethylene polyoxypropylene, phenethylphenol polyoxyethylene ether polyoxypropylene ether, isopropylphenyl phenethylphenol polyoxyethylene ether, styrene phenol polyoxyethylene ether, octylphenol polyoxyethylene ether, sec-octylphenol polyoxyethylene ether, nonylphenol polyoxyethylene ether, dinonylphenol polyoxyethylene ether, benzylphenol polyoxyethylene ether, fatty lauryl alcohol polyoxyethylene ether, oleyl alcohol polyoxyethylene ether, isothietrol polyoxyethylene ether, fatty acid polyoxyethylene ether, fatty amine polyoxyethylene ether, and methyl alcohol polyoxyethylene ether. The second emulsifier is selected from one or more of the following: glycerol esters, polyglycerol esters, glycol esters, EO-PO block polyethers, calcium dodecylbenzene sulfonate, stilbene-phenol polyoxymethylene condensate, triglyceride monostearate, arylphenol polyoxyethylene ether formaldehyde condensate, stearate, polyoxyethylene oleate, castor oil polyoxyethylene ether phosphate, sorbitan ester ether, polyglycerol fatty acid ester, succinate sulfonate, α-sulfofatty acid ester salt, and polyarylphenol ether sulfate.

2. The aqueous emulsion containing abamectin and thiazophos according to claim 1, characterized in that, The dispersant is selected from one or more of the following: high molecular weight polymer, sodium polystyrene acrylate, maleic rosin block polyether sulfonate ammonium salt, diisopropylnaphthalene sulfonate sodium salt, benzyl naphthalene sulfonate formaldehyde condensate sodium salt, styrene acrylic acid copolymer sodium salt, tristyrene-phenol polyoxyethylene ether phosphate triethanolamine salt, maleic rosin block polyether sulfonate ammonium salt, styrene-maleic anhydride copolymer sodium salt, maleic anhydride acrylic acid copolymer sodium salt, fatty alcohol polyoxyethylene polyoxypropylene ether, styrene-maleic anhydride copolymer sodium salt, alkanolamide polyoxyethylene ether phosphate, sodium lignosulfonate, calcium lignosulfonate, sodium diethylsuccinate sulfate, and cis-butadiene styrene sulfonate sodium salt.

3. The aqueous emulsion containing abamectin and thiazophos according to claim 1, characterized in that, The first emulsifier is selected from one or more of methyl alcohol polyoxyethylene ether and nonylphenol polyoxyethylene ether; The second emulsifier is selected from one or more of EO-PO block polyether and calcium dodecylbenzenesulfonate; The dispersant is selected from one or more of tristyrene-phenylphenol polyoxyethylene ether phosphate triethanolamine salt and benzyl naphthalene sulfonic acid formaldehyde condensate sodium salt.

4. The aqueous emulsion containing abamectin and thiazophos according to claim 3, characterized in that, The first emulsifier is methyl alcohol polyoxyethylene ether; The second emulsifier is EO-PO block polyether; The dispersant is tristyrene-phenylphenol polyoxyethylene ether phosphate triethanolamine salt or benzylnaphthalenesulfonic acid formaldehyde condensate sodium salt.

5. The aqueous emulsion containing abamectin and thiazophos according to any one of claims 1 to 4, characterized in that, The mass ratio of the first emulsifier, the second emulsifier, and the dispersant is 1-4:1-4:1-4; preferably 1-2:1-2:1-2; more preferably 1.5:1.5:

1.

6. The aqueous emulsion containing abamectin and thiazophos according to claim 1, characterized in that, The first emulsifier, the second emulsifier, and the dispersant are, in order, methyl alcohol polyoxyethylene ether, EO-PO block polyether, and tristyrene-phenylphenol polyoxyethylene ether phosphate triethanolamine salt, with mass contents of 3%, 3%, and 2%, respectively. The first emulsifier, the second emulsifier, and the dispersant are, in order, methyl alcohol polyoxyethylene ether, EO-PO block polyether, and sodium salt of benzyl naphthalene sulfonic acid formaldehyde condensate, with mass contents of 3%, 3%, and 2%, respectively. The first emulsifier, the second emulsifier, and the dispersant are, in order, methyl alcohol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, with mass contents of 3%, 3%, and 1%, respectively. The first emulsifier, the second emulsifier, and the dispersant are, in order, nonylphenol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, with mass contents of 3%, 3%, and 1%, respectively. The first emulsifier, the second emulsifier, and the dispersant are, in order, nonylphenol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, with mass contents of 1%, 1%, and 1%, respectively. The first emulsifier, the second emulsifier, and the dispersant are, in order, nonylphenol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, with mass contents of 1%, 1%, and 1.5%, respectively. The first emulsifier, the second emulsifier, and the dispersant are nonylphenol polyoxyethylene ether, calcium dodecylbenzene sulfonate, and sodium salt of benzyl naphthalene sulfonate formaldehyde condensate, respectively, with mass contents of 4%, 4%, and 1%.

7. The aqueous emulsion containing abamectin and thiazophos according to claim 1, characterized in that, The solvent is selected from one or more of solvent oil S-200, solvent oil S-150, solvent oil S-100, N,N-dimethyldecanoamide, and cyclohexanone; The co-solvent is selected from one or more of N-methylpyrrolidone, isophorone, dimethyl sulfoxide, and methyl oleate; The antifreeze is selected from one or more of urea, potassium chloride, ethylene glycol, propylene glycol, polyethylene glycol, and sodium chloride; The stabilizer is selected from one or more of butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, sodium carbonate, and o-hydroxydimethyl ketone.

8. The aqueous emulsion containing abamectin and thiazophos according to claim 7, characterized in that, The solvent is selected from one or more of solvent oil S-200 and solvent oil S-150; The co-solvent is selected from one or more of N-methylpyrrolidone and isophorone; The stabilizer is selected from one or more of butylated hydroxytoluene and butylated hydroxyanisole; The antifreeze agent is selected from one or more of ethylene glycol and polyethylene glycol.

9. The aqueous emulsion containing abamectin and thiazophos according to claim 1, characterized in that, The solvent, cosolvent, antifreeze, and stabilizer are solvent oil S-200, N-methylpyrrolidone, ethylene glycol, and butylated hydroxytoluene, respectively, with mass contents of 32%, 2%, 5%, and 1%, respectively. The solvent, cosolvent, antifreeze, and stabilizer are solvent oil S-150, isophorone, ethylene glycol, and butylated hydroxytoluene, respectively, with mass contents of 32%, 2%, 5%, and 1%. The solvent, cosolvent, antifreeze, and stabilizer are solvent oil S-150, isophorone, ethylene glycol, and butylated hydroxyanisole, respectively, with mass contents of 40%, 2%, 5%, and 1%. The solvent, cosolvent, antifreeze, and stabilizer are solvent oil S-150, isophorone, polyethylene glycol, and butylated hydroxyanisole, respectively, with mass contents of 15%, 2%, 8%, and 2%.

10. A method for preparing the aqueous emulsion containing abamectin and thiazophos according to any one of claims 1 to 9, comprising the following steps: S1) Mix the antifreeze and water evenly to obtain an aqueous phase; The active pharmaceutical ingredient, emulsifier, dispersant, solvent, cosolvent, and stabilizer are mixed to obtain an oil phase; S2) The above aqueous phase and oil phase are mixed to obtain an emulsion containing abamectin and thiazophos.

Images